Switch to: References

Add citations

You must login to add citations.
  1. The DSM, Big Pharma, and Clinical Practice Guidelines: Protecting Patient Autonomy and Informed Consent. Cosgrove - 2011 - International Journal of Feminist Approaches to Bioethics 4 (1):11-25.
    Researchers, investigative journalists, community physicians, ethicists, and policy makers have voiced strong concerns about the integrity of medicine. Specifically, questions have been raised about the ways in which financial conflicts of interest (FCOI) in the biomedical field may be compromising the integrity of the scientific research process and thus compromising patient care by disseminating imbalanced or even inaccurate information (Angell 2004). Indeed, many of us are no longer surprised when we read about settlements made by pharmaceutical companies—some totaling hundreds of (...)
    Direct download (4 more)  
     
    Export citation  
     
    Bookmark   3 citations  
  • Drug Firms, the Codification of Diagnostic Categories, and Bias in Clinical Guidelines.Lisa Cosgrove & Emily E. Wheeler - 2013 - Journal of Law, Medicine and Ethics 41 (3):644-653.
    The profession of medicine is predicated upon an ethical mandate: first do no harm. However, critics charge that the medical profession’s culture and its public health mission are being undermined by the pharmaceutical industry’s wide-ranging influence. In this article, we analyze how drug firms influence psychiatric taxonomy and treatment guidelines such that these resources may serve commercial rather than public health interests. Moving beyond a conflict-ofinterest model, we use the conceptual and normative framework of institutional corruption to examine how organized (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark   8 citations